Product Images Irinotecan Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 9 images provide visual information about the product associated with Irinotecan Hydrochloride NDC 70700-170 by Xiromed Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

2mL-Carton - 2ml carton

2mL-Carton - 2ml carton

This text is a description of a pharmaceutical product named Irinotecan hydrochloride trihydrate. Each mL contains 20mg of irinotecan hydrochloride trihydrate, 45mg of sorbitol, 0.9mg of lactic acid, and water for injection. It is a sterile, aqueous solution and it is available in a single-dose vial. It is a cytotoxic agent and must be diluted before use. The dosage and use instructions are available in the accompanying prescribing information. The manufacturer is Xiromed LLC, and it should be protected from light and freezing. Unused portions should be discarded.*

5mL-Carton - 5ml carton

5mL-Carton - 5ml carton

This is a description of a sterile aqueous solution of Irinotecan hydrochloride trihydrate, which must be diluted before use and used intravenously. It is intended for use as a cytotoxic agent, and it comes in a 5 mL single dose vial. It is important to discard any unused portion, and to store it at a temperature between 20-25°C (68-77°F), protected from both light and freezing. The product is manufactured by Xiromed LLC and is intended for intravenous use only, and it was manufactured in India.*

Irinotecan-Container-Label-100mg - irinotecan container label 100mg

Irinotecan-Container-Label-100mg - irinotecan container label 100mg

Irinotecan-Container-Label-40mg - irinotecan container label 40mg

Irinotecan-Container-Label-40mg - irinotecan container label 40mg

irinotecan spl figure 1

irinotecan spl figure 1

irinotecan spl figure 2

irinotecan spl figure 2

irinotecan-spl-figure-3 - irinotecan spl figure 3

irinotecan-spl-figure-3 - irinotecan spl figure 3

irinotecan-spl-figure-4 - irinotecan spl figure 4

irinotecan-spl-figure-4 - irinotecan spl figure 4

This text appears to be reporting some data related to a medical study or trial. The study involves an intervention called "Innotecan 5-FU," and the text reports the number of participants in the study (127 or 129). There is also a mention of a "median follow-up" of 15 months. The last line appears to be reporting a median value, possibly related to the duration of the study or the outcomes being measured, although the specific context is unclear from the provided text.*

irinotecan-spl-structure - irinotecan spl structure

irinotecan-spl-structure - irinotecan spl structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.